Pharmaceuticals News and Research

RSS

NanoBusiness 2009 conference to address nanotechnology advancements in various markets

The NanoBusiness Alliance, the world's leading nanotechnology trade association, today announced details of its expanded conference program for the 8th annual NanoBusiness 2009 conference and exhibition, which will held at McCormick Place in Chicago, IL, from September 8 – 10.

25 Aug 2009

CenterWatch senior edtior to deliver keynote address at KIKA’s U.S. User Group Meeting

KIKA Clinical Solutions announced that Sara Gambrill, Senior Editor of CenterWatch, will be a keynote speaker at KIKA’s U.S. User Group Meeting. KIKA is the leading provider of advanced EDC solutions for clinical trials, and creators of the Veracity Web-based platform for Clinical Asset Management. The User Group Meeting will take place October 21 and 22 in Boston.

25 Aug 2009

Tripep and Cosmix AG license RAS and mRNA Display Library technologies

Tripep and the German biotech company Cosmix AG have both licensed their respective technologies (RAS and mRNA Display Library) to a newly formed US company named Opsonic Therapeuticals Inc. within which Tripep’s RAS technology will be developed.

25 Aug 2009

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company’s New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to schedule an Advisory Committee meeting in late February 2010 to discuss the application.

25 Aug 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

25 Aug 2009

Malaysian biotechnology industry expected to grow by revenue at an average rate of 15 percent per year

Malaysia's plans for its biotechnology sector remain ambitious even with the recent global meltdown. By 2020 the government envisages this sector will employ up to 160,000 people and will contribute to 5% of Malaysia's GDP.

25 Aug 2009

Mark Booth joins Orexigen Therapeutics as the Chief Commercial Officer

Orexigen((R)) Therapeutics, Inc. today announced that Mark Booth has joined the Company as Chief Commercial Officer. Mr. Booth brings over 25 years of commercial and business development experience to Orexigen. Most recently he served as President of Takeda Pharmaceuticals North America (TPNA) where he presided over the commercial, medical and scientific affairs, business development and all support functions.

25 Aug 2009

Blue Spoon outlines a new strategy for pharmaceutical industries

Blue Spoon Consulting Group, LLC, today published a white paper that frames a new innovation space for strategy in the pharmaceutical industry. As momentum grows for performance-based contracting, connected health, and collaborative business models, drug companies will need to rethink their value proposition in a broader context.

25 Aug 2009

Value-Based Insurance Design improves health care services

As members of Congress continue to debate proposals for health care reform, the National Pharmaceutical Council (NPC) has released a new report on an important approach being used by leading edge employers for improving patient health outcomes - Value-Based Insurance Design (VBID).

25 Aug 2009

VHA's Non-Salary Cost Reduction program helps hospitals save supply costs

Floyd Memorial Hospital and Health Services in New Albany, Ind., turned to VHA Inc., the national health care network, to help it reduce supply expenses, and saved $3 million annually.

25 Aug 2009

FDA issues final approval for manufacturing and marketing Ranbaxy's Glycopyrrolate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Glycopyrrolate Tablets USP, 1 mg and 2 mg.

25 Aug 2009

Myoderm expands its portfolio to include drug procurement, management and distribution services

Myoderm, a leading global pharmaceutical supplier of comparator drugs for clinical research and clinical trials, has expanded its portfolio to include Distribution Management Services. This new capability provides their clients with an efficient solution for sourcing, managing, and distributing off-the-shelf, commercial drugs used in clinical trials.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

FDA issues marketing approval for APP Pharmaceuticals' Penicillin G potassium for Injection, USP

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ: APCVZ), announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market penicillin G potassium for Injection, USP, in two dosage strengths. Penicillin G is therapeutically equivalent to the reference drug PfizerPen™ G, which is marketed by the innovator Pfizer, Inc.

25 Aug 2009

Report assessing school-based policies that address the health of students released by AAFA

For over 8 million children with asthma, food allergies and related conditions, the school-house is a focal point for managing their diseases. Now for the second year in a row, the Asthma and Allergy Foundation of America (AAFA) has released a report assessing school-based policies that address student health for elementary, middle and high schools in all 50 states.

25 Aug 2009

FDA issues warning letter to Cambrex concerning its Italian API manufacturing facility

Cambrex Corporation (the "Company") announced that it has received a warning letter from the U.S. Food and Drug Administration ("FDA") relating to an inspection of the Company's generic active pharmaceutical ingredient ("API") manufacturing facility located in Milan, Italy in March 2009. The observations noted in the warning letter are primarily related to the collection and maintenance of certain laboratory data.

25 Aug 2009

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer.

24 Aug 2009

Advanced Instruments' next-generation website facilitates easy retrieval of product and application information

Advanced Instruments has introduced a next-generation Web site that dramatically enhances the customer's online business experience when purchasing osmometers, cryoscopes, and microbiological laboratory instruments.

24 Aug 2009

Encorium releases second-quarter 2009 results

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced its financial results for the second quarter ended June 30, 2009.

24 Aug 2009

ZoomMed announces registration of American subsidiary ZoomMedUSA

ZoomMed Inc., creator of the ZRx Prescriber, announces that it has registered an American subsidiary under the name ZoomMedUSA Inc. in order to export the ZRx Prescriber to the United States.

24 Aug 2009

Pharmaceuticals News and Research

NanoBusiness 2009 conference to address nanotechnology advancements in various markets

CenterWatch senior edtior to deliver keynote address at KIKA’s U.S. User Group Meeting

Tripep and Cosmix AG license RAS and mRNA Display Library technologies

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Malaysian biotechnology industry expected to grow by revenue at an average rate of 15 percent per year

Mark Booth joins Orexigen Therapeutics as the Chief Commercial Officer

Blue Spoon outlines a new strategy for pharmaceutical industries

Value-Based Insurance Design improves health care services

VHA's Non-Salary Cost Reduction program helps hospitals save supply costs

FDA issues final approval for manufacturing and marketing Ranbaxy's Glycopyrrolate tablets

Myoderm expands its portfolio to include drug procurement, management and distribution services

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

FDA issues marketing approval for APP Pharmaceuticals' Penicillin G potassium for Injection, USP

Report assessing school-based policies that address the health of students released by AAFA

FDA issues warning letter to Cambrex concerning its Italian API manufacturing facility

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Advanced Instruments' next-generation website facilitates easy retrieval of product and application information

Encorium releases second-quarter 2009 results

ZoomMed announces registration of American subsidiary ZoomMedUSA

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring